A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma

NCT05256472 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma
First-line Treatment

Interventions

DRUG: AK104
DRUG: axitinib

Sponsor

Akeso